Compare KE & PRME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KE | PRME |
|---|---|---|
| Founded | 1961 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electrical Products | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 564.2M | 553.2M |
| IPO Year | 2014 | 2022 |
| Metric | KE | PRME |
|---|---|---|
| Price | $24.67 | $3.12 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 6 |
| Target Price | ★ $28.00 | $7.56 |
| AVG Volume (30 Days) | 166.1K | ★ 2.4M |
| Earning Date | 05-05-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 66.18 | 18.18 |
| EPS | ★ 1.13 | N/A |
| Revenue | ★ $1,431,378,000.00 | $4,632,000.00 |
| Revenue This Year | N/A | $7.06 |
| Revenue Next Year | $4.57 | $47.01 |
| P/E Ratio | $21.79 | ★ N/A |
| Revenue Growth | N/A | ★ 55.28 |
| 52 Week Low | $21.60 | $2.67 |
| 52 Week High | $32.47 | $6.94 |
| Indicator | KE | PRME |
|---|---|---|
| Relative Strength Index (RSI) | 53.49 | 42.70 |
| Support Level | $23.59 | $2.73 |
| Resistance Level | $26.77 | $3.72 |
| Average True Range (ATR) | 0.84 | 0.22 |
| MACD | 0.08 | -0.06 |
| Stochastic Oscillator | 65.38 | 19.89 |
Kimball Electronics Inc is a contract electronic manufacturing services company. The company is engaged in producing durable electronics for the automotive, medical, industrial, and public safety end markets. The company's engineering, manufacturing, and supply chain services utilize common production and support capabilities. It is also engaged in producing safety-critical electronic assemblies for its automotive customers. Geographically, it has business units located in the United States, China, Mexico, Poland, Romania, and Thailand. The company derives maximum revenue from Mexico.
Prime Medicine Inc is a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression. Its program, PM577 for Wilson Disease, is designed to initially correct the H1069Q mutation in the ATP7B gene and is supported by preclinical data showing targeted correction and restoration of copper homeostasis in animal models. In addition, PM647 is being developed for alpha-1 antitrypsin deficiency, or AATD, another liver targeted disease with substantial unmet need.